Kyoko Takahashi Lin
Lawyers
Filters
IHS Markit joint venture with CME Group
We are advising IHS Markit on its agreement with CME Group to combine their post-trade services into a new joint venture
Comcast subsidiary FreeWheel acquires BeeswaxIO
Davis Polk is advising FreeWheel, a subsidiary of Comcast Corporation, on its acquisition of BeeswaxIO Corporation. Financial terms of the deal were not disclosed.
FreeWheel, a Comcast…
BRP Group $258.1 million follow-on offering of common stock
Davis Polk advised BRP Group, Inc. on its $258.1 million follow-on offering of 8,750,000 shares of Class A common stock. The shares of Class A common stock are listed on the Nasdaq Global…
IHS Markit $44 billion merger with S&P Global
Davis Polk is advising IHS Markit on its all-stock merger with S&P Global that values IHS Markit at an enterprise value of $44 billion. Under the terms of the merger agreement, each…
Bertelsmann $2.175 billion acquisition of Simon & Schuster
Davis Polk is advising Bertelsmann on the $2.175 billion acquisition by its global trade book publishing group, Penguin Random House, of Simon & Schuster from ViacomCBS. The transaction…
Assurant acquisition of HYLA Mobile
Davis Polk is advising Assurant on its acquisition of mobile device trade-in innovator HYLA Mobile. The transaction is expected to close by the end of 2020, subject to regulatory and other…
Morgan Stanley $7 billion acquisition of Eaton Vance
Davis Polk is advising Morgan Stanley on its $7 billion acquisition of Eaton Vance Corp. The acquisition is subject to customary closing conditions and is expected to close in the second…
Pactiv Evergreen $574 million IPO
Davis Polk advised Pactiv Evergreen Inc. (formerly known as Reynolds Group Holdings Limited) on its $574 million initial public offering of 41,026,000 shares of common stock. The shares of…
Gilead Sciences $21 billion acquisition of Immunomedics
Davis Polk is advising Gilead Sciences, Inc. in its acquisition of Immunomedics, Inc. for $88.00 per share in cash. The transaction, which values Immunomedics at approximately $21 billion,…
CureVac $245.3 million IPO
Davis Polk advised CureVac N.V. on its $245.3 million initial public offering of 15,333,332 of its common shares, which includes 1,999,999 common shares from the full exercise of the…